Results 181 to 190 of about 114,558 (301)

Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. [PDF]

Drug Metab Rev, 2021
Yadav J, El Hassani M, Sodhi J, Lauschke VM, Hartman JH, Russell LE.   +5 more
europepmc   +1 more source

Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma

Advanced Science, EarlyView.
This study reported renal‐clearable bio‐orthogonal near‐infrared fluorogenic probes (BGRs) that specifically imaging and urinalysis of granzyme B for dynamic evaluation of RCC immunotherapy. BGRs not only differentiate immunotherapeutic responses in orthotopic RCC mice, but also enable sensitive optical urinalysis of granzyme B in clinical specimens ...
Xingyue Yang, Baoshuai Liang, Liangmin Fu, Weiliang Deng, Yuyan Jiang, Weiping Xu, Jinwei Chen, Ya Zhou, Ke Wu, Jiaguo Huang   +9 more
wiley   +1 more source

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. [PDF]

ACS Infect Dis, 2020
O'Donnell J, Tanudra A, Chen A, Hines D, Tommasi R, Mueller J.   +5 more
europepmc   +1 more source

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

Advanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale, Marie Celine Lefevre, Alessio Carmignani, Maria Cristina Ceccarelli, Matteo Battaglini, Attilio Marino, Gianni Ciofani   +6 more
wiley   +1 more source

Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug OxaliTEX and Their Significance to Antitumor Response. [PDF]

Mol Pharm
He G, Thiabaud GD, Shelton KA, Segura LJ, Arambula JF, Sessler JL, Finch RA, Siddik ZH.   +7 more
europepmc   +1 more source

Multimodal Multiorgan‐on‐a‐Chip Platform for Probing Liver‐Tumor Interactions and Advancing Prodrug Screening

Advanced Science, EarlyView.
This work introduces a multimodal multi‐OoC platform that overcomes current limitations in liver‐tumor interaction studies and prodrug screening. By integrating dynamic microfluidic circuits, electrochemical sensing, and mass analysis, this platform enables non‐invasive, longitudinal monitoring of drug metabolism and hepatotoxicity, offering a ...
Dan Wang, Yisong Huang, Weijian Zhao, Tian Chen, Siyu Bai, Denghui Guo, Mengying Wang, Yaoyao Zhao, Liang Zhao, Guangsheng Guo, Xiayan Wang   +10 more
wiley   +1 more source

Kinsenoside Targets IDH1 to Restore Microglial Immune‐Metabolic Homeostasis for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
Dysregulated TCA cycle contributes to Alzheimer's disease (AD) pathogenesis. Here, we show that microglial isocitrate dehydrogenase 1 (IDH1) is a critical driver. Elevated IDH1 disrupts citrate metabolism and mitochondrial function, exacerbating AD pathology.
Qianqian Li, Yajin Liao, Yan‐bo Zhao, Hongxing Wu, Tong Jin, Shuoshuo Li, Yuhan Liu, Peng Li, Songying Ouyang, Zekai Li, YuTing Xia, Qian Hua, Rui‐Yuan Pan, Zengqiang Yuan   +13 more
wiley   +1 more source

The preclinical pharmacokinetics of Tolinapant-A dual cIAP1/XIAP antagonist with in vivo efficacy. [PDF]

Pharmacol Res Perspect
Martins V, Ward G, Smyth T, Reader M, Chessari G, Johnson C, Wilsher N.   +6 more
europepmc   +1 more source

Pharmacokinetics of FK 506: Preclinical and clinical studies [PDF]

, 1990
Cadoff, E, Fung, JJ, Imventarza, O, Iwasaki, K, Jain, A, Krajack, A, Nagase, K, Starzl, TE, Todo, S, Venkataramanan, R, Warty, V   +10 more
core  

A FAP‐Targeted SMDC Platform Enables Synergistic Radionuclide–Chemotherapy with PET‐Guided Evaluation

Advanced Science, EarlyView.
A fibroblast activation protein (FAP)‐targeted small molecule–drug conjugate (SMDC) platform is developed to integrate PET imaging with synergistic radionuclide–chemotherapy. Linker chemistry governs stability, exposure, and tolerability, with the VC linker providing superior in vivo performance.
Ruitao Yang, Hongxin Li, Zexin Xu, Baocheng Chen, Ningjie Li, Yuhua Zhong, Kongzhen Hu   +6 more
wiley   +1 more source